非小细胞肺癌中的PET/MRI
肺癌仍是全球癌症相关死亡的首要原因,非小细胞肺癌(NSCLC)占80%-85%。PET/MR是一种相对较新且有前景的无辐射技术,结合MRI的软组织对比与功能信息及PET的代谢信息,在脑、肝、肾上腺和骨等常见转移部位检测转移的敏感性优于CT和PET/CT。PET/MR目前尚非常规临床工具,但成像技术进步、协议优化和大规模研究可能使其成为肺癌个体化管理的关键组成部分。
要点
- NSCLC占肺癌的80%-85%,准确成像对分期、治疗计划和随访至关重要。
- PET/MR无辐射,软组织对比分辨率和细胞水平功能信息优于CT和PET/CT。
- PET/MR对脑、肝、肾上腺和骨等常见转移部位检测转移的敏感性优于CT和PET/CT。
核心结论
- PET/MR目前尚非常规临床工具,但成像技术进步、协议优化和大规模研究可能使其成为肺癌个体化管理的关键组成部分。
研究设计与样本
- 本文为综述,检索范围原文未报告。
主要发现
- 肺癌仍是全球癌症相关死亡的首要原因,NSCLC占80%-85%。
- PET/MR结合MRI的软组织对比分辨率和特定序列(如弥散加权和灌注序列)提供的细胞水平功能信息与PET的代谢信息。
- PET/MR对脑、肝、肾上腺和骨等常见转移部位检测转移的敏感性优于CT和PET/CT。
临床怎么用
- 原文未据此给出推荐。
局限性
- PET/MR目前尚非常规临床工具。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Lung cancer remains the leading cause of cancer-related deaths worldwide, with nonsmall cell lung cancer (NSCLC) accounting for 80%-85% of cases. Accurate imaging is critical for staging, treatment planning, and follow-up. While CT and PET/CT are standard imaging modalities, PET/MR is a relatively new and promising radiation free technique combining the potentiality of MRI with the metabolic information of PET scans, allowing undeniable advantages including: superior contrast resolution, particularly in soft tissues; functional information through specific MRI sequences (eg, diffusion-weighted and perfusion sequences), reflecting changes at a cellular level; and more superior sensitivity compared to CT and PET/CT for detecting metastases in common metastatic sites such as the brain, liver, adrenal glands, and bone. These advantages position PET/MR as a valuable tool in comprehensive lung cancer staging. While it is not yet a routine clinical tool, ongoing advancements in imaging technology, protocol optimization, and large-scale studies may establish PET/MR as a key component in the personalized management of lung cancer.
引用
- Alorfi F, Bomanji J, Bertoletti L, et al. PET/MRI in Non-Small Cell Lung Cancer (NSCLC). Semin Nucl Med. 2025. PMID: 40050130. doi:10.1053/j.semnuclmed.2025.02.009
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。